Archive | Of Interest

The Tale of a Double-Edged Sword Protecting the Heart from Metastatic Melanoma Tumor and its Treatment with Pembrolizumab

Cardio-oncology is a field of medicine emerging at the intersection of cardiology and oncology.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Is it feasible to change the immunotherapy dose schedule for a patient in complete response?

Immunotherapy represents a novel form of therapy in many ways, and it may not need to be given continuously.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

What Role for Anti-TNFs in Addressing Immune Checkpoint Inhibitor AEs?

Source: The Center For Biosimilars, February 2020 While immune checkpoint inhibitors have shown great promise in treating cancer, they are associated with immune-related adverse events (AE), many of which can be severe. One of the most common AEs that leads to discontinuation of immune checkpoint inhibitors is immune-related enterocolitis, or inflammation of the digestive tract. […]

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Eosinophilic Fasciitis: A Rare Immune-Related Adverse Effect of Immune Checkpoint Inhibitor Therapy

A report describing 4 new cases of eosinophilic fasciitis (EF) occurring in patients with metastatic melanoma or lung adenocarcinoma receiving single-agent immune checkpoint inhibitor therapy at a tertiary cancer center was published in the Oncologist.1

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest